Ocular Therapeutix, Inc. (OCUL)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 3
in 9 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Ocular Therapeutix topped consensus on both the top and bottom line in the second fiscal quarter of 2026, reported August 3, 2026, with EPS of -$0.35 topping the -$0.40 estimate by $0.05 and revenue of $13.5 million topping the $13.2 million estimate (+2%). Revenue was essentially flat year over year, rising 0.1% to about $13.5 million (up from about $13.5 million a year ago), reflecting results from its ophthalmic portfolio built on its bioresorbable hydrogel technology, including products such as DEXTENZA and ReSure Sealant. Profitability remained shaped by a high gross margin, with gross profit of roughly $11.5 million and gross margin at about 85%, while operating income was -$82.1 million. Net income was -$78.8 million, down 16.1% year over year from roughly -$67.8 million a year ago. For the next period, consensus calls for EPS of -$0.36 on revenue of $14.3 million.
Next report — what to expect
Ocular Therapeutix, Inc. (OCUL) reports on November 3, 2026. Wall Street’s next-period consensus calls for EPS of -$0.36 on revenue of $14.3 million. For trailing context, revenue was up +0.1% year over year last quarter. OCUL has beaten EPS in 3 of its 8 most recent quarters.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. develops ophthalmic treatments in the healthcare biotechnology field. Listed on the NASDAQ as OCUL, the company sells eye-care products built around a proprietary bioresorbable hydrogel technology and recorded $51.8 million in revenue in FY2025, with marketed and pipeline programs both focused on diseases of the eye.
Today's Snapshot
The day ended with OCUL 1.7% lower at 6.50, in line with a weaker sector. Shares changed hands at about half of its usual level. Earnings are due from OCUL on 3 November.
Trading Volume
Below 10d avg (3.3M)
1.8M
vs S&P 500 Today
Underperforming Market
-1.14%
Updated: October 23, 2026 at 20:26 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$6.84 - $9.60Sell
- RSI (14)32.59Neutral
- Stochastic %K (14, 3, 3)30.29Neutral
- MACD Level (12, 26)-0.74Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.